Beta Drugs Ltd

Beta Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 June 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 20 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s near-term prospects.

Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in price momentum, supported by a complex mix of technical indicators. Despite a recent upgrade from a mildly bearish to a sideways technical trend, the stock’s price action and momentum oscillators reveal a nuanced picture for investors navigating this evolving landscape.

At Rs 1,760, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Beta Drugs Ltd locked at its upper circuit of 19.24% on 12 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its valuation parameters, moving from an expensive to a very expensive rating. This change, coupled with a recent 6.49% intraday price surge, invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks.

Beta Drugs Ltd is rated Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a comprehensive assessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 09 June 2026, providing investors with the latest perspective on the company’s position in the market.

Beta Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, signalling a transition from a sideways trend to a mildly bearish stance. This change is underscored by a combination of mixed technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest caution for investors amid recent price declines.

Beta Drugs Ltd is rated 'Sell' by MarketsMOJO. This rating was assigned on 14 May 2026, reflecting a comprehensive evaluation of the stock’s prospects. However, all fundamentals, returns, and financial metrics discussed here are current as of 16 May 2026, providing investors with the latest insight into the company’s position.

Beta Drugs Ltd., a Himachal Pradesh-based pharmaceutical manufacturer, reported a marginal increase in consolidated net profit for Q4 FY26, posting ₹9.05 crores compared to ₹9.03 crores in Q4 FY25, representing a modest year-on-year growth of 1.12%. The ₹1,343 crore market capitalisation company saw its stock plunge 9.38% following the results announcement, reflecting investor disappointment with deteriorating profitability margins despite revenue growth.